HAS2 and acinar cell carcinoma: USP17 and HAS2 expressions were more prominent in acinar adenocarcinoma (ADC) tumors (82% and 89%, respectively), and in dysplasia (68% and 75%, respectively), compared to squamous cell carcinoma (SqCC; 15% and 17%, respectively; Table 1 and Figures 7Ad, e, g, h j and k).